SavedAdd your journal

Journals / Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi / 2021 / Cilt: 31 - Sayı: 1

MEDICATION RELATED OSTEONECROSIS OF THE JAWBONES: A REVIEW

İLACA BAĞLI ÇENE KEMİĞİ OSTEONEKROZU: BİR DERLEME

Ferhat AYRANCI
Mehmet Melih ÖMEZLİ
Damla TORUL
Emine ÖRNEK AKDOĞAN
Pages
115–123
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The aim of this review is to present the etiopathology and current treatment strategies of MRONJ in the light of the literature.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Medication Related Osteonecrosis of the Jaws (MRONJ) is a complication characterized by the appearance of necrotic bone in the maxilla and mandible, resulting from the use of bisphosphonates as well as drugs with antiosteoclastic and antiangiogenic activity.
📊
Key Findings & Data:No consensus has been reached regarding the treatment protocol that will prevent the economic and social burden of the patients by providing optimum management of this unique complication which constitutes a serious problem for both physicians and patients.
💡
Conclusion & Impact:The aim of this review is to present the etiopathology and current treatment strategies of MRONJ in the light of the literature.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Medication Related Osteonecrosis of the Jaws (MRONJ) is a complication characterized by the appearance of necrotic bone in the maxilla and mandible, resulting from the use of bisphosphonates as well as drugs with antiosteoclastic and antiangiogenic activity. No consensus has been reached regarding the treatment protocol that will prevent the economic and social burden of the patients by providing optimum management of this unique complication which constitutes a serious problem for both physicians and patients. The aim of this review is to present the etiopathology and current treatment strategies of MRONJ in the light of the literature.

Özet

İlaca Bağlı Çene Kemiği Osteonekrozu (MRONJ) bifosfonatlar yanında antiosteoklastik ve antianjiyojenik aktiviteye sahip ilaçlarınkullanımı sonucu ortaya çıkan, maksilla ve mandibulada nekrotik kemik varlığı ile karakterize bir komplikasyondur. Hem hekimlerhem de hastalar için ciddi bir problem oluşturan bu özgün komplikasyonun optimum düzeyde yönetimini sağlayarak hastalarınekonomik ve sosyal mağduriyetlerini önleyecek tedavi protokolü ile ilgili bir fikir birliği bulunmamaktadır. Bu derlemenin amacıMRONJ’un etyopatolojisi ve güncel tedavi stratejilerini literatür ışığında sunmaktır.

🔖

Cite This Article

AYRANCI, F., ÖMEZLİ, M. M., TORUL, D., AKDOĞAN, E. Ö. (2022). MEDICATION RELATED OSTEONECROSIS OF THE JAWBONES: A REVIEW. Atatürk Üniversitesi Diş Hekimliği Fakültesi Dergisi, Cilt: 31 - Sayı: 1, 115–123. https://ajindex.com/articles/451618

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Aslan Ö, Vural H, Kömürcü Ş, Özet A. Kemoterapi Alan kanser hastalarina verilen eğitimin kemoterapi semptomlarina etkisi. CÜ Hemsirelik Yüksekokulu Derg 2006;10:15-28
  2. Ribeiro GH, Chrun ES, Dutra KL, Daniel FI, Grando LJ. Osteonecrosis of the jaws: a review and update in etiology and treatment. Braz J Otorhinolaryngol 2018;84:102-8
  3. Manea HC, Urechescu HC, Balica NC, Pricop MO, Baderca F, Poenaru M, Horhat ID, Jifcu EM, Closca RM, Sarau CA. Bisphosphonates-induced osteonecrosis of the jaw - epidemiological, clinical and histopathological aspects. Rom J Morphol Embryol 2018;59:825-31
  4. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7
  5. Crepin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaw induced by clodronate, an alkylbiphosphonate: case report and literature review. Eur J Clin Pharmacol 2010;66:547-54
  6. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw -2009 update. Aust Endod J 2009;35:119-30
  7. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G, 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8
  8. King R, Tanna N, Patel V. Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review. Oral Surg Oral Med Oral Pathol Oral Radiol 2019;127:289-99
  9. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O'Ryan F. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56
  10. Topaloglu G, Koseoglu OT, Karaca C, Kosemehmetoglu K. The effect of chronic dental inflammation on development of Stage 0 medication-related osteonecrosis of the jaw. J Craniomaxillofac Surg 2017;45:1158-64
  11. Kang MH, Lee DK, Kim CW, Song IS, Jun SH. Clinical characteristics and recurrence-related factors of medication-related osteonecrosis of the jaw. J Korean Assoc Oral Maxillofac Surg 2018;44:225-31
  12. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12:6222s-30s
  13. Lemound J, Muecke T, Zeller AN, Lichtenstein J, Eckardt A, Gellrich NC. Nasolabial Flap improves healing in medication-related osteonecrosis of the jaw. J Oral